Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
The Greatest Important Oils for Crohn’s Illness
Crohn's disease is a type of inflammatory bowel disease (IBD) that affects over half a million people in the United States. People with...
Can diabetes trigger pores and skin situations? Right here’s what you have to know
diabetes is no longer a disease of the chosen few, but has now become a general lifestyle disease that affects millions (men, women and...